Ethnographic Museum of the University of Zurich

CymaBay Presents Results on the Potential of Seladelpar in Treatment of Patients with Primary Biliary Cholangitis at ACG 2023

Retrieved on: 
Monday, October 23, 2023
Ethnographic Museum of the University of Zurich, Patient, American College, IL-31, Itch, UDCA, The Duke of Edinburgh's International Award - Canada, Hope, Pathology, Conditional sentence, NRS, Liver, ALP, American College of Gastroenterology, HIV disease progression rates, PBC, Ursodeoxycholic acid, Risk, European Association for the Study of the Liver, Research and development, Cholestatic pruritus, Alkaline phosphatase, Primary biliary cholangitis, University, EASL, Cholestasis, Atopic dermatitis, Therapy, Doctor of Philosophy, Pharmaceutical industry, Research, MD

VANCOUVER, British Columbia, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, announced today the presentation of findings from its post-hoc analysis of the Phase 3 ENHANCE study of seladelpar for the treatment of primary biliary cholangitis (PBC), showing baseline intensity of patient-reported pruritus was associated with higher levels of serum IL-31. The presentation, named the recipient of this year’s International Award by the American College of Gastroenterology, will be presented by Professor Andreas E. Kremer, MD, Ph.D., MHBA, a leading authority in cholestatic pruritus from the University of Zurich. Featured results included novel aspects of the anti-pruritic and anti-cholestatic mechanisms of seladelpar, CymaBay’s first-in-class oral, selective PPARδ agonist, or "delpar," being investigated for the treatment of patients with PBC.

Key Points: 
  • Featured results included novel aspects of the anti-pruritic and anti-cholestatic mechanisms of seladelpar, CymaBay’s first-in-class oral, selective PPARδ agonist, or "delpar," being investigated for the treatment of patients with PBC.
  • The data were previously presented at the European Association for the Study of the Liver (EASL)’s The International Liver Congress™ 2023 in Vienna, Austria.
  • “These results offer a glimmer of hope in that they link IL-31 levels in patients with PBC to itch.
  • Elevated risk due to ELF was identified in 43.2% of patients who currently meet guidelines for second-line treatment vs. 27.2% within patient groups not recommended for second-line treatment.

A Glimpse Into the Central Nervous System Wins the 13th Annual Nikon Small World in Motion Competition

Retrieved on: 
Tuesday, September 26, 2023
Infection, Neuron, Senior, Ethnographic Museum of the University of Zurich, Central nervous system, University, Nikon Instruments, Schizophrenia, SARS-CoV-2, Spectrum, Oxygen, Communication, Microscopy, DSM-IV codes, Chicken, Research, Cell, Nature, Nervous system, CRM, Comprehension, Institut Pasteur Korea, Synapse, Pasteur Institute, Axon, Camera, Pharmaceutical industry, Microscope, Motion

MELVILLE, N.Y., Sept. 26, 2023 /PRNewswire/ -- Nikon Instruments Inc. today unveiled the winners of the 13th annual Nikon Small World in Motion Video Competition. This year's first place prize was awarded to Dr. Alexandre Dumoulin for his 48-hour time-lapse video of developing neurons connecting to the opposite side of the central nervous system in a chick embryo. Developed at the University of Zurich, Dumoulin's video plays a significant role in understanding the potential deviations in neurodevelopmental disorders that occur in the central nervous system, such as autism spectrum disorder and schizophrenia.

Key Points: 
  • With the potential to better understand neurodevelopmental disorders, this year's Nikon Small World in Motion winning video has universal applications
    MELVILLE, N.Y., Sept. 26, 2023 /PRNewswire/ -- Nikon Instruments Inc. today unveiled the winners of the 13th annual Nikon Small World in Motion Video Competition .
  • They are connected with long extensions known as axons and these axons traverse the nervous system before eventually forming synapses.
  • Dumoulin's video showcases these lengthy axons projecting across the midline, which serves as a boundary between the two hemispheres of the central nervous system.
  • He went on to say, "The nervous system is an immensely complex and intricate system composed of a myriad of units that are connected to one another.

Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer

Retrieved on: 
Tuesday, September 19, 2023
Ethnographic Museum of the University of Zurich, Employment, University, RSU, Therapy, Immunogenic cell death, CSO, Seagen, Cancer, Genentech, Doctor of Philosophy, Molecular biology, Genetics, Patient, SAN, STRO, VCS, Drug discovery, ADC, BLA, IND, Compensated emancipation, Pharmaceutical industry, Pharma, Biochemistry, Biotechnology, Spacecraft, Pfizer

SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced the appointment of Hans-Peter Gerber, Ph.D., as Chief Scientific Officer, effective September 18, 2023.
  • Dr. Gerber brings over 25 years of drug discovery and development experience to Sutro, with extensive scientific background and expertise in ADCs, targeted oncology, and novel biotherapeutic platforms.
  • Prior to joining Sutro, Dr. Gerber served as Chief Scientific Officer at Codeable Therapeutics, an ADC startup company focusing on the development of next generation ADCs that induce immunogenic cell death.
  • In connection with Dr. Gerber’s appointment as Chief Scientific Officer, the Compensation Committee of Sutro’s Board of Directors granted to Dr. Gerber 175,000 shares of Sutro stock options and 150,000 restricted stock units (RSUs) of Sutro common stock.

Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells

Retrieved on: 
Wednesday, April 12, 2023
Ethnographic Museum of the University of Zurich, University, Cell membrane, G protein-coupled receptor, Neurodegenerative disease, Nature Communications, Cancer, GPCR, Drug discovery, Research, SEMA4D, Library, Eurosport 1, Fine chemical

ROCHESTER, N.Y., April 12, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D today announced a new publication in the March 30, 2022 issue of Nature Communications describing a novel way that the ActivMAb® platform can be used for functional studies and drug discovery of the “hard to drug” class of membrane-associated G protein-coupled receptors (GPCRs) and ion channels.

Key Points: 
  • GPCRs are a very important class of drug targets because of their critical role in physiological processes.
  • However, low expression levels and dependence on the mammalian membrane environment for conformational stability and function make them difficult targets for drug selection.
  • The authors demonstrate that the ActivMAb technology overcomes these limitations by engineering directed protein evolution libraries in a mammalian signaling environment allowing GPCR expression that is amenable to structural studies.
  • We believe this new technology application will further enhance our ActivMab® offering, and we look forward to sharing it with our partners.”

Oncorus Announces Exclusive Licensing Agreement with Gaeta Therapeutics Ltd. for Use of Locally Delivered Interleukin-12 (IL-12) via Oncolytic Viral Expression in Combination with Immune Checkpoint Inhibitors

Retrieved on: 
Thursday, November 11, 2021
Synthetic, Gaeta, IL-12, Safety, University, SITC, Cancer, PD-L1, Private Securities Litigation Reform Act, Therapy, Strategic management, Mark (given name), Investor, Neoplasm, HSV, RNA, Transgene, Society, Pembrolizumab, COVID-19, FLT3LG, PD-1, Annual report, CD4, RNA transfection, Risk, Annual general meeting, GLOBE, Ethnographic Museum of the University of Zurich, CCL4, Immunology, Business development, Immunotherapy, CD8, Nasdaq, Patient, Vaccine, Pharmaceutical industry

Known to activate and expand CD8, CD4 TH1 and natural killer cells, IL-12 is a transgene of notable interest in the immune-oncology space.

Key Points: 
  • Known to activate and expand CD8, CD4 TH1 and natural killer cells, IL-12 is a transgene of notable interest in the immune-oncology space.
  • IL-12 in combination with immune checkpoint blockade has demonstrated the ability to augment treatment response in certain patients versus immune checkpoint inhibitor treatment alone, said Theodore (Ted) Ashburn, M.D., Ph.D., President and Chief Executive Officer at Oncorus.
  • IL-12 is one of five immunomodulatory payloads in our lead viral immunotherapy product candidate, ONCR-177.
  • At Oncorus, we are focused on driving innovation to deliver next-generation viral immunotherapies to transform outcomes for cancer patients.